Smart maintenance: tailored drug after transplant aims to keep myeloma at bay

NCT ID NCT06483100

First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 25 times

Summary

This study tests a personalized approach for people with newly diagnosed multiple myeloma who have had a stem cell transplant. After transplant, participants receive a drug called elranatamab as maintenance therapy, with the dose and duration guided by a sensitive blood test that detects tiny amounts of remaining cancer (MRD). The goal is to improve how long the cancer stays away, while reducing unnecessary treatment. About 65 adults will take part in this phase 2 trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Washington University School of Medicine

    RECRUITING

    St Louis, Missouri, 63110, United States

    Contact

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.